Dr. Torti

medicine
Galera Therapeutics
New Zealand

Biography

Dr. Torti joined NEA in 2007 and focuses on investments in biopharmaceuticals, medical devices, and healthcare services. He has been actively involved in the firm’s private and public investments in healthcare, including Peplin (acquired by LEO Pharma), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), Alimera Sciences, Cadence Pharmaceuticals, Dermira, Galera Therapeutics, Neotract, Novast Pharmaceuticals, Rigel Pharmaceuticals, and Solta Medical. Dr. Torti received his MD from the University of North Carolina School of Medicine, his MBA with distinction from Harvard Business School, and his BA with highest honors from the University of North Carolina, where he was a Morehead Scholar.

Research Intrest

 medicine

Global Scientific Words in Medical Sciences